Literature DB >> 7730446

Role of nitric oxide and melanogenesis in the accomplishment of anticryptococcal activity by the BV-2 microglial cell line.

E Blasi1, R Barluzzi, R Mazzolla, B Tancini, S Saleppico, M Puliti, L Pitzurra, F Bistoni.   

Abstract

In the present paper, we investigated the involvement of cryptococcal melanogenesis and macrophage nitric oxide (NO) production in the accomplishment of anticryptococcal activity by microglial effector cells, using the murine cell line BV-2. We demonstrate that the constitutive levels of anticryptococcal activity exerted by BV-2 cells is significantly enhanced upon interferon gamma plus lipopolysaccharide treatment. The phenomenon, which occurs with no enhancement of phagocytic activity, is associated with the production of high levels of NO and is abolished by addition of NG-monomethyl-L-arginine. Comparable patterns of results are observed employing either unopsonized or opsonized microbial targets, the latter microorganisms being markedly more susceptible to BV-2 cell antimicrobial activity. Furthermore, melanization of Cryptococcus neoformans significantly reduces its susceptibility to BV-2 antimicrobial activity, regardless of the fact that activated macrophages or opsonized microorganisms have been employed. In conclusion, our results provide evidence that NO-dependent events are involved in the fulfillment of anticryptococcal activity by activated microglial cells and that fungal melanization is a precious escamotage through which C. neoformans overcomes host defenses.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7730446     DOI: 10.1016/0165-5728(95)00016-u

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  26 in total

1.  Melanin, melanin "ghosts," and melanin composition in Cryptococcus neoformans.

Authors:  Y Wang; P Aisen; A Casadevall
Journal:  Infect Immun       Date:  1996-07       Impact factor: 3.441

2.  Requirement for CD4(+) T lymphocytes in host resistance against Cryptococcus neoformans in the central nervous system of immunized mice.

Authors:  K L Buchanan; H A Doyle
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

Review 3.  Role of microglia in central nervous system infections.

Authors:  R Bryan Rock; Genya Gekker; Shuxian Hu; Wen S Sheng; Maxim Cheeran; James R Lokensgard; Phillip K Peterson
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

Review 4.  Impact of melanin on microbial virulence and clinical resistance to antimicrobial compounds.

Authors:  Joshua D Nosanchuk; Arturo Casadevall
Journal:  Antimicrob Agents Chemother       Date:  2006-11       Impact factor: 5.191

Review 5.  Microglia as a pharmacological target in infectious and inflammatory diseases of the brain.

Authors:  R Bryan Rock; Phillip K Peterson
Journal:  J Neuroimmune Pharmacol       Date:  2006-06       Impact factor: 4.147

Review 6.  Immune response and immunotherapy to Cryptococcus infections.

Authors:  Qing Zhou; William J Murphy
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

7.  Effect of cytokines on anticryptococcal activity of human microglial cells.

Authors:  M M Lipovsky; A E Juliana; G Gekker; S Hu; A I Hoepelman; P K Peterson
Journal:  Clin Diagn Lab Immunol       Date:  1998-05

8.  Expression of inducible nitric oxide synthase in rat pulmonary Cryptococcus neoformans granulomas.

Authors:  D Goldman; Y Cho; M Zhao; A Casadevall; S C Lee
Journal:  Am J Pathol       Date:  1996-04       Impact factor: 4.307

9.  CNLAC1 is required for extrapulmonary dissemination of Cryptococcus neoformans but not pulmonary persistence.

Authors:  Mairi C Noverr; Peter R Williamson; Ryan S Fajardo; Gary B Huffnagle
Journal:  Infect Immun       Date:  2004-03       Impact factor: 3.441

10.  Susceptibility of melanized and nonmelanized Cryptococcus neoformans to the melanin-binding compounds trifluoperazine and chloroquine.

Authors:  Y Wang; A Casadevall
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.